Back to News
Market Impact: 0.4
Candel Reports 24.5-Month Survival In Phase 2a NSCLC Study
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Candel Therapeutics reported final Phase 2a data showing median overall survival of 24.5 months for aglatimagene besadenovec plus valacyclovir in advanced non-small cell lung cancer patients who had responded inadequately to immune checkpoint inhibitors. The positive clinical result could support further development of the therapy in a high-unmet-need oncology population and is likely material for CADL shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
CADL0.82
More News
- Broadcom to lend Anthropic up to $42 billion to lease its chips, filing says
- Nike Warns Sales Slump Will Worsen This Fiscal Year
- $8.2B acquisition validates AI-picked chip stock: +20% since June
- Nuveen CEO on Schroders Deal, Plans for Combined Company
- New Mexico wants Meta to pay up to $40 billion in penalties after data privacy trial
- Markets slip on dollar pressure, but this IT stock is up 10% today